Search

Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exacerbate the pathological condition, and therein lies the main cause of post-traumatic neural degeneration, which then ends with the chronic phase. In recent years, therapeutic interventions addressing different neurodegenerative mechanisms have been proposed, but have met with limited success when translated into clinical settings. The underlying reasons for this are that the pathogenesis of SCI is a continued multifactorial disease, and the treatment of only one factor is not sufficient to curb neural degeneration and resulting paralysis. Recent advances have led to the development of biomaterials aiming to promote in situ combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative-factor-based treatments as well as potential delivery options to treat SCIs. [ABSTRACT FROM AUTHOR]

Bicontinuous jammed emulsions (known as bijels) are Pickering emulsions where oil and water are both continuous phases. These interconnected structures, stabilized by colloidal nanoparticles at the oil–water interface, have been used in a wide range of applications. Among these, catalysis and encapsulation of solutes has showed promising potential, but the low mechanical properties of the systems limit their use. Here it is proposed that the use of a hydrophobic monomer able to polymerize in bulk and form a biphasic porous structure with polymer and water as immiscible phases. The final system is stabilized by colloidal nanoparticles made of hydroxyapatite, and the system's ability to release both hydrophilic and hydrophobic drugs has been demonstrated. The strategy has been proven to be highly versatile and may be tuned with a diversity of monomers and nanoparticles to satisfy specific industrial and medical needs. [ABSTRACT FROM AUTHOR]

Current pharmacological and surgical therapies for the central nervous system (CNS) show a limited capacity to reduce the damage progression; that together with the intrinsic limited capability of the CNS to regenerate greatly reduces the hopes of recovery. Among all the therapies proposed, the tissue engineering strategies supplemented with therapeutic stem cells remain the most promising. Neural tissue engineering strategies are based on the development of devices presenting optimal physical, chemical, and mechanical properties which, once inserted in the injured site, can support therapeutic cells, limiting the effect of a hostile environment and supporting regenerative processes. Thus, this review focuses on the employment of hydrogel and nanofibrous scaffolds supplemented with stem cells as promising therapeutic tools for the central and peripheral nervous systems in preclinical and clinical applications.